Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
In BriefThis Month in JNM

This Month in JNM

Journal of Nuclear Medicine June 2023, 64 (6) 10A;
  • Article
  • Info & Metrics
  • PDF
Loading

Discussions with leaders: Kostakoglu talks with Vincent Rajkumar, MD, from the Mayo clinic, about collaborative and pioneering work in establishing influential guidelines in the treatment of myeloma.

Page 831

18F-labeled SSTR tracers: Leupe and colleagues provide an update of currently available clinical data regarding 18F-labeled somatostatin analog tracers and justification for clinical applications.

Page 835

PET/CT and osteosarcoma management: Oh and colleagues offer an educational overview of clinical aspects of osteosarcoma management and assess the role of 18F-FDG PET/CT, with special focus on pediatric and young adult patients.

Page 842

18F-Fluciclovine PET in glioblastoma: Nabavizadeh and colleagues report on a study assessing the value of 18F-fluciclovine PET for differentiating pseudoprogression from tumor progression in patients with suspected radiographic recurrence of glioblastoma.

Page 852

68Ga-DOTA-MGS5 PET/CT in MTC: von Guggenberg and colleagues describe imaging results with this 68Ga-labeled minigastrin analog to evaluate cholecystokinin-2 receptor expression status and local recurrence/metastases in patients with advanced medullary thyroid cancer.

Page 859

Imaging tumor status in prostate cancer: al Jalali and colleagues explore the use of [68Ga]PSMA and [18F]FDHT in PET imaging as a potential substitute for analysis of prostate cancer tumors, particularly in evaluating androgen receptor expression.

Page 863

Patient-reported outcomes for PC: Gudenkauf and colleagues detail development of a patient-reported outcome measure for radionuclide therapy in prostate cancer, with utility as a standardized tool to monitor relevant symptoms and toxicities.

Page 869

Signaling network response to TAT: Qin and colleagues investigate cellular responses to targeted α-particle therapy and demonstrate the radiosensitizing potential of histone deacetylase inhibitors for 225Ac-PP-F11N in cholecystokinin B receptor–positive tumors.

Page 873

PRRT in high liver tumor burden: Gococo-Benore and colleagues assess the risk of hepatotoxicity for patients with gastroenteropancreatic neuroendocrine tumors and very high liver tumor burden undergoing peptide-receptor radionuclide therapy.

Page 880

124I-MIBG dosimetry-guided 131I-MIBG therapy: Maric and colleagues report on the efficacy and safety of 124I-MIBG dosimetry-guided high-activity 131I-MIBG therapy in patients with advanced pheochromocytoma or neuroblastoma.

Page 885

PSMA dosimetry in HGG: Graef and colleagues investigate [177Lu]Lu-PSMA therapy in high-grade glioma, with a focus on intratherapeutic dosimetry.

Page 892

PSMA PET/CT criteria and prognosis: Lunger and colleagues explore the prognostic utility of conventional biochemical/imaging response criteria and 68Ga-PSMA11 PET-based criteria for overall survival in metastatic hormone-sensitive and castration-resistant prostate cancer treated with taxane-based chemotherapy.

Page 896

68Ga-PSMA PET for PB recurrence SRT: Sonni and colleagues use 68Ga-PSMA-11 PET/CT to evaluate patterns of prostate bed recurrence and guide salvage radiotherapy in prostate-specific antigen persistence or biochemical recurrence after radical prostatectomy.

Page 902

PSMA expression in CRPC: Calderoni and colleagues examine PSMA expression in patients with castration-resistant prostate cancer and compare PET/CT response with prostate-specific antigen variation as a prognostic factor for progression-free and overall survival.

Page 910

PSMA-positive LNs and ENRT templates: Trapp and colleagues analyze PSMA PET/CT–positive lymph nodes and compare results with those from several templates proposed for salvage elective nodal radiotherapy, emphasizing the role of imaging in individualization of treatment.

Page 918

[225Ac]Ac-ofatumumab and lymphoma: Longtine et and colleagues describe preparation of 225Ac-labeled anti-CD20 ofatumumab and evaluate its in vitro characteristics and therapeutic efficacy in a murine model of disseminated human lymphoma.

Page 924

Strain analysis from ECG-gated PET MPI: Huang and colleagues detail development of a measure of longitudinal, radial, and circumferential myocardial strain at rest and during pharmacologic stress using 82Rb PET electrocardiography-gated myocardial perfusion imaging.

Page 932

PET and pulmonary fibrosis: Isser and colleagues use a 64Cu-labeled platelet glycoprotein VI fusion protein targeting extracellular matrix fibers as a PET tracer to observe longitudinal remodeling in a bleomycin-induced pulmonary fibrosis mouse model.

Page 940

Pretreatment 131I-omburtamab imaging and dosimetry: Pandit-Taskar and colleagues perform 131I-omburtamab imaging and dosimetric analysis for estimation of absorbed dose to the cerebrospinal fluid compartment before 131I-omburtamab therapy for leptomeningeal disease.

Page 946

AI-denoised low-dose 64Cu-DOTATATE PET: Loft and colleagues ask whether artificial intelligence approaches can be used to restore visual quality and lesion detection in PET images acquired with <50 MBq of 64Cu-DOTATATE in patients with neuroendocrine neoplasms.

Page 951

Total-body 68Ga-FAPI parametric imaging: Chen and colleagues explore the pharmacokinetics of 68Ga-FAPI-04 PET/CT in pancreatic and gastric cancer and conduct parametric imaging of dynamic total-body data compared with SUV-based imaging.

Page 960

Perfusion index with [18F]MK6240: Guehl and colleagues research the potential utility of the early phase of imaging with [18F]MK6240, with high affinity and selectivity for hyperphosphorylated tau, as a surrogate index of cerebral perfusion.

Page 968

Explainable AI: Bradshaw and colleagues summarize key arguments for and against the use of “explainable artificial intelligence” from the perspectives of data science, clinical practice, and bioethics.

Page 976

Ultrahigh-resolution small-animal PET: Kang and colleagues report on an ultrahigh-resolution small-animal PET scanner that can provide a resolution approaching 0.6 mm to visualize mouse brain function and serve as a promising molecular imaging tool for neuroscience research.

Page 978

Theranostic radiopharmaceuticals: Urbain and colleagues review currently available education and accreditation offerings and policies for theranostics around the world and discuss educational and proficiency challenges.

Page 986

68Ga-FAPI-46 urachal remnant: Maliha and colleagues present an example of potentially confounding incidental uptake in a urachal remnant on preoperative 68Ga-FAPI-46 PET/CT.

Page 992

Incidental bronchial findings on 18F-PSMA PET/CT: Orciuolo and colleagues describe a case of large-airway PSMA localization in a patient with chronic airway inflammation, highlighting the potential for false-positive findings.

Page 993

  • © 2023 by the Society of Nuclear Medicine and Molecular Imaging.
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 64 (6)
Journal of Nuclear Medicine
Vol. 64, Issue 6
June 1, 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
This Month in JNM
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
This Month in JNM
Journal of Nuclear Medicine Jun 2023, 64 (6) 10A;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
This Month in JNM
Journal of Nuclear Medicine Jun 2023, 64 (6) 10A;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • This Month in JNM
  • This Month in JNM
  • This Month in JNM
Show more This Month in JNM

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire